Clinical development of MVA-based therapeutic cancer vaccines

Expert Review of Vaccines

Volumn 7, Issue 7, 2008, Pages 889-893

  Acres, Bruce ^a   Bonnefoy, Jean Yves ^a  

^a TRANSGENE S A   (France)

Author keywords

Cancer immunotherapy; Modified vaccinia virus Ankara; Poxvirus vaccine; Therapeutic viral vaccine

Indexed keywords

CANCER VACCINE; CISPLATIN; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MELANOMA ANTIGEN; MONOPHENOL MONOOXYGENASE; MUCIN 1; ONCOFETAL ANTIGEN; PROSTATE SPECIFIC ANTIGEN; SMALLPOX VACCINE; TG4010; TROVAX; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANTIGEN EXPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DENDRITIC CELL; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; MODIFIED VACCINIA VIRUS ANKARA; MONOTHERAPY; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SMALLPOX; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR CELL; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ANTIGENS, NEOPLASM; CANCER VACCINES; GENETIC VECTORS; HUMANS; NEOPLASMS; VACCINIA VIRUS;

EID: 51349124402     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.7.889     Document Type: Review

References (57)

1. Moss B. Vaccinia virus: a tool for research and vaccine development. Science 252(5013), 1662-1667 (1991).
2. Dick G. Routine smallpox vaccination. Br. Med. J. 3(5767), 163-166 (1971).
3. Kempe CH. The end of routine smallpox vaccination in the United States. Pediatrics 49(4), 489-492 (1972).
4. Buller RM, Smith GL, Cremer K, Notkins AL, Moss B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 317(6040), 813-815 (1985).
5. Acres B, Dott K, Stefani L, Kieny MP. Directed cytokine expression in tumor cells in vivo using recombinant vaccinia virus. Ther. Immunol. 1(1), 17-23 (1994).
6. Foloppe J, Kintz J, Futin N et al. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther. (2008) (Epub ahead of print) DOI: 10.1038/gt.2008.82.
7. Shen Y, Nemunaitis J. Fighting cancer with vaccinia virus: teaching new tricks to an old dog. Mol. Ther. 11(2), 180-195 (2005).
8. Kieny MP, Lathe R, Drillien R et al. Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature 312(5990), 163-166 (1984).
9. Brochier B, Kieny MP, Costy F et al. Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature 354(6354), 520-522 (1991).
10. Kieny MP, Gautier C, Tomasetto C et al. Vaccination against polyoma virus (PyV) tumors using vaccinia-PyV recombinants: a major tumor-specific transplantation antigen (TSTA) epitope resides within the C-terminal segment of middle-T protein. Int. J. Cancer 45(1), 185-189 (1990).
11. Hareuveni M, Gautier C, Kieny MP, Wreschner D, Chambon P, Lathe R. Vaccination against tumor cells expressing breast cancer epithelial tumor antigen. Proc. Natl Acad. Sci. USA 87(23), 9498-9502 (1990).
12. Kantor J, Irvine K, Abrams S, Kaufman H, DiPietro J, Schlom J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J. Natl Cancer Inst. 84(14), 1084-1091 (1992).
13. Cole DJ, Wilson MC, Baron PL et al. Phase I study of recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge. Hum. Gene Ther. 7(11), 1381-1394 (1996).
14. Scholl SM, Balloul JM, Le Goc G et al. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J. Immunother. 23(5), 570-580 (2000).
15. Wallack MK, Sivanandham M, Balch CM et al. A Phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 75(1), 34-42 (1995).
16. Taylor J, Paoletti E. Fowlpox virus as a vector in non-avian species. Vaccine 6(6), 466-468 (1988).
17. Wild F, Giraudon P, Spehner D, Drillien R, Lecocq JP. Fowlpox virus recombinant encoding the measles virus fusion protein: protection of mice against fatal measles encephalitis. Vaccine 8(5), 441-442 (1990).
18. Leong KH, Ramsay AJ, Boyle DB, Ramshaw IA. Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus. J. Virol. 68(12), 8125-8130 (1991).
19. Marshall JL, Gulley JL, Arlen PM et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol. 23(4), 720-731 (2005).
20. Arlen PM, Gulley JL, Parker C et al. A randomized Phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin. Cancer Res. 12(4), 1260-1269 (2006).
21. Gulley JL, Arlen PM, Tsang KY et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin. Cancer Res. 14(10), 3060-3069 (2008).
22. Tartaglia J, Perkus ME, Taylor J et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 188(1), 217-232 (1992).
23. Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc. Natl Acad. Sci. USA 93(21), 11349-11353 (1996).
24. Mayr A, Hochstein-Mintzel V, Stickl H. [Derivation, characterization and use of the attenuated vaccinia strain MVA]. Infection 3, 6-14 (1975).
25. Stickl H, Hochstein-Mintzel V, Mayr A et al. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA). Dtsch Med. Wochenschr. 99, 2386-2392 (1974).
26. Mayr A, Stickl H, Müller HK, Danner K, Singer H. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism. Zentralbl. Bakteriol. (B) 167(5-6), 375-390 (1978).
27. Gómez CE, Nájera JL, Krupa M, Esteban M. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr. Gene Ther. 8(2), 97-120 (2008).
28. Trevor KT, Hersh EM, Brailey J, Balloul JM, Acres B. Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2. Cancer Immunol. Immunother. 50(8), 397-407 (2001).
29. Erbs P, Findeli A, Kintz J et al. Modified vaccinia virus Ankara as a vector for suicide gene therapy. Cancer Gene Ther. 15(1), 18-28 (2008).
30. McConkey SJ, Reece WH, Moorthy VS et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9(6), 729-735 (2003).
31. Gilbert SC, Moorthy VS, Andrews L et al. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 24(21), 4554-4561 (2006).
32. Fournillier A, Gerossier E, Evlashev A et al. An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses. Vaccine 25(42), 7339-7353 (2007).
33. Mwau M, Cebere I, Sutton J et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J. Gen. Virol. 85(Pt 4), 911-919 (2004).
34. Rochlitz C, Figlin R, Squiban P et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J. Gene Med. 5(8), 690-699 (2003).
35. Mulryan K, Ryan MG, Myers KA et al. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. Mol. Cancer Ther. 1(12), 1129-1137 (2002).
36. Meyer RG, Britten CM, Siepmann U et al. A Phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer Immunol. Immunother. 54(5), 453-467 (2005).
37. +-derived dendritic cell vaccination: a Phase I trial in metastatic melanoma. Clin. Cancer Res. 10(16), 5381-5390 (2004).
38. Smith CL, Dunbar PR, Mirza F et al. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int. J. Cancer 113(2), 259-266 (2005).
39. Hawkins RE, Dangoor A, Keilholz U et al. Phase I/II trial of a PrimeBoost therapeutic vaccine in stage III/IV metastatic melanoma. J. Clin. Oncol. 24(18 Suppl.), 8030 (2006).
40. Amato RJ. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy. Expert Opin. Biol. Ther. 7(9), 1463-1469 (2007).
41. Cao J, Hernandez-McClain J, Willis R et al. Activity of MVA 5T4 alone or in combination with either interleukin-2 (IL-2) or interferon-α (IFN) in patients (Pts) with metastatic renal cell cancer (MRCC). ASCO Meeting Abstracts 25, 3069 (2007).
42. Harrop R, Drury N, Shingler W et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin. Cancer Res. 13(15 Pt 1), 4487-4494 (2007).
43. Amato RJ, Drury N, Naylor S et al. Vaccination of prostate cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax): a Phase II trial. J. Immunother. 31(6), 577-585 (2008).
44. Acres B, Limacher JM. MUC1 as a target antigen for cancer immunotherapy. Expert Rev. Vaccines 4(4), 493-502 (2005).
45. Scholl SM, Balloul JM, Le Goc G et al. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J. Immunother. 23(5), 570-580 (2000).
46. Scholl S, Squiban P, Bizouarne N et al. Metastatic breast tumor regression following treatment by a gene-modified vaccinia virus expressing MUC1 and IL-2. J. Biomed. Biotechnol. 2003(3), 194-201 (2003).
47. Pantuck AJ, van Ophoven A, Gitlitz BJ et al. Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J. Immunother. 27(3), 240-253 (2004).
48. Acres B. Cancer immunotherapy: Phase II clinical studies with TG4010 (MVA-MUC1-IL2). J. BUON 12(Suppl. 1), S71-S75 (2007).
49. Dreicer R, Ahmann FR, Pantuck AJ et al. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) in patients with prostate cancer with biochemical failure. J. Clin. Oncol. 2005 ASCO Annual Meeting Proceedings. 23(16S), 4518 (2005).
50. Banu E, Rixe O, Linassier C et al. A Phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal cell carcinoma (RCC). J. Clin. Oncol. 2005 ASCO Annual Meeting Proceedings 24(18S), 2581 (2006).
51. Velu T, Ramlau R, Quoix E et al. A Phase II study evaluating the clinical efficacy of TG4010 (MVA-MUC1-IL2) in association with chemotherapy in patients with non small cell lung cancer. J. Clin. Oncol. 2005 ASCO Annual Meeting Proceedings 23(16S), 7132 (2005).
52. Ramlau R, Quoix E, Rolski J et al. A Phase II study of TG4010 (MVA-MUC1-IL2) in association with chemotherapy in patients with stage III/IV non small cell lung cancer. J. Thor. Oncol. 3(7), 735-744 (2008).
53. Ramlau R, Westeel V, Papai Z et al. Randomized Phase IIb trial evaluating the therapeutic vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 8023).
54. Bavarian Nordic www.bavarian-nordic.com
55. Oxford BioMedica. Clinical trials overview www.oxfordbiomedica.co.uk/ clinical.htm
56. Transgene www.transgene.fr/us/index.php
57. Oxford BioMedica www.oxfordbiomedica.co.uk